Boehringer Ingelheim has signed a licensing, development and commercialisation deal worth more than $700m (£573.85m) with Indian pharma company Lupin for the latter’s MEK inhibitor compound LNP3794.
US biotech company Insilico Medicine has developed a new artificial intelligence (AI) system for drug discovery, known as GENTRL.
Vertex Pharmaceuticals has agreed to acquire US-based biotech company Semma Therapeutics for $950m (£784.66m) in an all-cash deal with an aim to develop curative cell-based treatments for type 1 diabetes.
HiFiBiO Therapeutics, a US biotherapeutics company, which has developed a single-cell analytics platform for extensive immune profiling, has completed a $67m (£54.86m) Series C financing round.
Immatics Biotechnologies and Celgene have signed a collaboration and option deal worth up to $1.59bn (£1.3bn) to develop novel adoptive cell therapies against multiple cancers.
OncoNano Medicine, Inc. today announced that it has been awarded $15.4m (£12.6m) from the Cancer Prevention and Research Institute of Texas (CPRIT) to advance ONM-500, one of OncoNano’s innovative oncology product candidates.
Zogenix has agreed to acquire Modis Therapeutics, a California-based biopharma company focused on developing disease-modifying therapies for rare genetic diseases, in a cash-cum-stock deal worth over $400m (£325.72m).
ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), and Freenome, a biotechnology company that has pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw, announced that they have entered a biomarker development collaboration in which ADC Therapeutics will use Freenome’s platform to identify patients who are most likely to respond to treatment with ADCT-402 (loncastuximab tesirine).
Cantargia and BioWa have signed an extension of the licence agreement around the BioWa proprietary POTELLIGENT technology for production of Cantargia’s antibody drug candidate CAN04, which gives Cantargia broader rights to use the technology.
Gilead Sciences has finalised its 10-year global research and development deal, worth up to $5.05bn (£4.11bn), with Belgium-based Galapagos following regulatory clearances.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.